CZ20003846A3 - Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva - Google Patents

Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva Download PDF

Info

Publication number
CZ20003846A3
CZ20003846A3 CZ20003846A CZ20003846A CZ20003846A3 CZ 20003846 A3 CZ20003846 A3 CZ 20003846A3 CZ 20003846 A CZ20003846 A CZ 20003846A CZ 20003846 A CZ20003846 A CZ 20003846A CZ 20003846 A3 CZ20003846 A3 CZ 20003846A3
Authority
CZ
Czechia
Prior art keywords
acetylglucosamine
carrier
composition
foam
nag
Prior art date
Application number
CZ20003846A
Other languages
Czech (cs)
English (en)
Inventor
Simon Murch
Ian W. French
Original Assignee
Glucogenics Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glucogenics Pharmaceuticals Inc. filed Critical Glucogenics Pharmaceuticals Inc.
Publication of CZ20003846A3 publication Critical patent/CZ20003846A3/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CZ20003846A 1998-04-17 1999-03-12 Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva CZ20003846A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002234936A CA2234936C (en) 1998-04-17 1998-04-17 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine

Publications (1)

Publication Number Publication Date
CZ20003846A3 true CZ20003846A3 (cs) 2002-03-13

Family

ID=4162337

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20003846A CZ20003846A3 (cs) 1998-04-17 1999-03-12 Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva

Country Status (8)

Country Link
EP (1) EP1071432A1 (no)
JP (1) JP2002512195A (no)
CA (1) CA2234936C (no)
CZ (1) CZ20003846A3 (no)
HU (1) HUP0101514A3 (no)
IL (1) IL139072A0 (no)
NO (1) NO20005223L (no)
PL (1) PL343634A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918452T3 (es) 2007-02-19 2022-07-15 Marine Polymer Tech Inc Composiciones hemostáticas y regímenes terapéuticos
KR101098581B1 (ko) * 2009-01-09 2011-12-26 서울대학교산학협력단 Abh 항원을 이용한 염증질환 개선용 조성물
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
JP6144254B2 (ja) 2011-04-15 2017-06-07 マリン ポリマー テクノロジーズ,インコーポレーテッド ポリ−n−アセチルグルコサミンナノファイバを用いた疾患の治療
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CA2967722A1 (en) * 2014-11-26 2016-06-02 Evonik Rohm Gmbh Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Also Published As

Publication number Publication date
CA2234936A1 (en) 1999-10-17
IL139072A0 (en) 2001-11-25
NO20005223D0 (no) 2000-10-17
NO20005223L (no) 2000-11-20
JP2002512195A (ja) 2002-04-23
EP1071432A1 (en) 2001-01-31
HUP0101514A3 (en) 2003-07-28
CA2234936C (en) 2004-06-29
HUP0101514A2 (hu) 2001-11-28
PL343634A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
US6046179A (en) Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
US9782348B2 (en) Ingestible formulations for transient, noninvasive reduction of gastric volume
Chen et al. Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities
CZ295932B6 (cs) Prostředek pro podání léčiva pro lokalizované uvolňování léčiva v gastrointestinálním traktu zvířete a použití tohoto prostředku
SK284539B6 (sk) Použitie nikotínu, farmaceutické kompozície a farmaceutický kombinačný produkt
Leopold et al. Eudragit® E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD)
US10765709B2 (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
JP2015503583A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用の方法
WO2015018344A1 (zh) 穿心莲内酯在制备炎症性肠病的药物中的应用、穿心莲内酯肠溶靶向微丸及其制备方法
US20230210790A1 (en) Gel for use in gastrointestinal endoscopy and endodermal, epidermal, and other mucosal uses
JP2015510928A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用方法
CZ20003846A3 (cs) Kompozice pro léčbu zánětlivého onemocnění střev dávkováním N-acetylglukosaminu do tlustého střeva
JP5404406B2 (ja) 細胞外マトリクスの分解の阻害
JP2018039831A (ja) 排尿頻度を減少させるための医薬製剤およびその使用の方法
JP6161734B2 (ja) グリコサミノグリカンを含有する医薬製剤
CN101432004A (zh) 用于控制的碳水化合物消化的联合治疗
Saffran Oral colon-specific drug delivery with emphasis on insulin
TWI446915B (zh) 玻尿酸混合物用於製造治療或預防黏膜相關病變或疾病之組成物的用途
CN112999146B (zh) 一种可注射黏附性水凝胶及其制备方法与应用
US20160151296A1 (en) Long delayed release laxative
Asteria et al. Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases
Das Pharmacotherapy of inflammatory bowel disease
Kulkarni et al. CODES TECHNOLOGY: A NOVEL APPROACH FOR COLON TARGET-A REVIEW ARTICLE
EP1100481A2 (en) Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease
Bell Drugs used in the management of gallstones